Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Grows By 40.8%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 77,000 shares, an increase of 40.8% from the October 31st total of 54,700 shares. Approximately 5.8% of the shares of the company are short sold. Based on an average daily volume of 337,300 shares, the short-interest ratio is presently 0.2 days.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC purchased a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned about 1.08% of Sonoma Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Price Performance

Shares of NASDAQ:SNOA remained flat at $2.79 on Friday. 36,732 shares of the stock traded hands, compared to its average volume of 625,256. The stock has a market cap of $3.74 million, a price-to-earnings ratio of -0.56 and a beta of 1.38. Sonoma Pharmaceuticals has a 1-year low of $2.52 and a 1-year high of $9.37. The stock has a fifty day moving average price of $2.90 and a 200 day moving average price of $1.54.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.